SOTRET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOTRET (SOTRET).
Binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription to reduce sebum production, normalize follicular keratinization, and inhibit Propionibacterium acnes growth.
| Metabolism | Primarily hepatic via CYP450 isoenzymes (CYP2B6, CYP2C8, CYP3A4) to active metabolites: 4-oxo-isotretinoin, tretinoin, and 4-oxo-tretinoin. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites (approximately 60-80% in urine) and fecal elimination (15-30%). |
| Half-life | Terminal elimination half-life: 18-20 hours in adults; steady-state achieved after 5-7 days of dosing. |
| Protein binding | 99.9% bound to albumin, primarily to albumin. |
| Volume of Distribution | Approximately 2.5-5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: Approximately 25% due to extensive first-pass metabolism; absorption significantly increased (up to 2-fold) when taken with a high-fat meal. |
| Onset of Action | Oral: Clinical improvement in acne vulgaris typically observed within 4-8 weeks. |
| Duration of Action | Duration of therapeutic effect continues for weeks to months after discontinuation; remission may persist for prolonged periods. |
| Action Class | Retinoids- First generation |
| Brand Substitutes | Isac 20mg Capsule, Reznin 20mg Capsule, Popout 20mg Capsule, Tretiva 20 Capsule, Systroin 20 Capsule, Trato 10mg Soft Gelatin Capsule, Isoden 10mg Soft Gelatin Capsule, Adclin 10mg Soft Gelatin Capsule, Aknea 10 Softgel Capsule, Mavtron 10mg Soft Gelatin Capsule, Saferet 30mg Capsule, Nidtroin 30mg Capsule, Isofree 30mg Capsule, Acutret 30 Capsule, Isotroin 0.05% Gel, Acno Gel, Isofeel 40 Softgel Capsule, Tretiva 40 Capsule, Nutret 5mg Capsule, Isotino 5mg Capsule, Isokon 5mg Capsule, Isotane 5mg Capsule, Retizo 5mg Capsule |
Oral isotretinoin 0.5-1 mg/kg/day divided twice daily for 15-20 weeks.
| Dosage form | CAPSULE |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For CrCl 30-59 mL/min, reduce dose by 50%. No adjustment for CrCl ≥60 mL/min. |
| Liver impairment | Contraindicated in Child-Pugh class B or C. For Child-Pugh class A, reduce dose by 50% and monitor LFTs. |
| Pediatric use | For children ≥12 years: 0.5-1 mg/kg/day (max 2 mg/kg/day) divided twice daily for 15-20 weeks. For <12 years, safety not established. |
| Geriatric use | No specific dose adjustment; use lowest effective dose (0.5 mg/kg/day) due to increased risk of adverse effects (e.g., hypertriglyceridemia, musculoskeletal pain). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOTRET (SOTRET).
| Breastfeeding | Isotretinoin is excreted in human breast milk. Case reports indicate an M/P ratio of approximately 1.0. Due to the potential for serious adverse effects in the nursing infant, breastfeeding is contraindicated during isotretinoin therapy and for at least 8 days after the last dose. |
| Teratogenic Risk | SOTRET (isotretinoin) is a known human teratogen. Exposure during pregnancy, particularly between weeks 3 and 6 of gestation, is associated with a high risk of major congenital malformations including craniofacial defects (micrognathia, cleft palate), cardiovascular abnormalities, central nervous system anomalies (hydrocephalus, microcephaly), thymic and parathyroid gland abnormalities. Therefore, isotretinoin is contraindicated in pregnant women or those of childbearing potential unless they meet strict conditions of pregnancy prevention. |
■ FDA Black Box Warning
Isotretinoin is contraindicated in women of childbearing potential unless they meet strict conditions for pregnancy prevention due to its teratogenicity. It is also associated with increased risk of suicidal thoughts and behaviors, pseudotumor cerebri, and severe skin reactions.
| Serious Effects |
["Pregnancy or childbearing potential without strict pregnancy prevention","Breastfeeding","Hypersensitivity to isotretinoin or any component","Concomitant use of tetracyclines (increased risk of pseudotumor cerebri)","Vitamin A supplements (risk of hypervitaminosis A)"]
| Precautions | ["Teratogenicity: Absolute contraindication in pregnancy; must ensure negative pregnancy test and use two forms of contraception.","Psychiatric disorders: May cause depression, psychosis, suicidal ideation; monitor mental health.","Pseudotumor cerebri: Risk increases with concomitant tetracyclines.","Hypertriglyceridemia: Monitor lipids; may lead to pancreatitis.","Hepatotoxicity: Monitor liver enzymes; avoid alcohol.","Skeletal hyperostosis: Long-term use may cause premature epiphyseal closure.","Nocturnal vision loss: Rare; caution with night driving.","Inflammatory bowel disease: Rare reports; discontinue if symptoms occur."] |
Loading safety data…
| Fetal Monitoring | Prior to initiation, confirm negative pregnancy test. Monthly in-treatment pregnancy tests are mandatory. Liver function tests, lipid panel, and renal function should be monitored at baseline and monthly due to potential hepatotoxicity, hyperlipidemia, and renal effects. Patients should be monitored for signs of pseudotumor cerebri (headache, visual disturbances). |
| Fertility Effects | Isotretinoin may transiently affect spermatogenesis in males, but data do not indicate permanent sterility. In females, isotretinoin does not impair fertility; however, due to teratogenicity, effective contraception is mandatory during therapy and for 1 month after discontinuation. |